Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 13/20 | 1.00 |
| ▸ | GRM8 | O00222 | 1/20 | 1.00 |
| ▸ | GRM7 | Q14831 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | PNLIP | P16233 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20166019 | 1.00 | GRM4 (1.00) | GRM4GRM8GRM7NPC1RAB9A | |
| SCHEMBL2529723 | 0.89 | GRM4 (0.80) | GRM4GRM8GRM7NPC1RAB9A | |
| SCHEMBL2535702 | 0.86 | GRM4 (0.76) | GRM4GRM8GRM7NPC1RAB9A | |
| SCHEMBL2532528 | 0.85 | GRM4 (0.73) | GRM4GRM8GRM7NPC1RAB9A | |
| SCHEMBL2533496 | 0.83 | GRM4 (0.74) | GRM4GRM8GRM7NPC1RAB9A | |
| SCHEMBL2530375 | 0.83 | GRM4 (0.74) | GRM4GRM8GRM7NPC1RAB9A | |
| SCHEMBL2529601 | 0.81 | GRM4 (0.67) | GRM4GRM8GRM7NPC1RAB9A | |
| SCHEMBL2533211 | 0.79 | GRM4 (0.65) | GRM4GRM8GRM7NPC1RAB9A | |
| SCHEMBL2535716 | 0.78 | GRM4 (0.67) | GRM4GRM8GRM7NPC1RAB9A | |
| SCHEMBL2528005 | 0.76 | GRM4 (0.64) | GRM4GRM8GRM7NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12156879-B2 | Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy | UNIVERSITY OF CONNECTICUT (US) | 2024-12-03 | — | — | US | claimed |
| US-12156879-B2 | Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy | UNIVERSITY OF CONNECTICUT (US) | 2024-12-03 | — | — | US | disclosed |
| EP-3541812-B1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-06-14 | — | — | EP | disclosed |
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12156879-B2 | Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy | BACE1, PSEN1, PSEN2 | GRM4 17/4885GRM8 22/4885GRM7 15/4885 |
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | GRM7, GRM2, GRM1 | GRM4 11/4885GRM8 13/4885GRM7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.